Addiction and Impulse Control Disorders are wired the same.

 

This article, published on December 10, 2009 in Addiction Professional shows that Pathological Gamblers respond to the same medications as other addicts, supporting the contention that addictions to substances and behaviours are different manifestations of the same patho-physiology

 

Nashville, TN — Pathological gambling can be successfully treated with medications that decrease urges and increase inhibitions, according to researchers at the annual meeting of the American College of Neuropsychopharmacology (ACNP). Researchers found positive outcomes in gamblers treated with medications often used for substance addictions.

Dr. Jon Grant and his team at the University of Minnesota used tasks that measure cognition to identify what motivates this extreme type of gambling behavior. They enrolled men and women with a primary diagnosis of pathological gambling in one of three medication studies. Study sites varied in size from 70 to 100 participants.

In order to group individuals into categories that address differences in their biology, Grant separated pathological gamblers into two major subtypes: gamblers who are driven by urge (i.e., individuals who report gambling when the desire becomes too strong to control) and those who do not show normal inhibition of impulsive behaviors (i.e., individuals who report being unable to restrict behaviors even when urges are minimal or virtually non-existent).

In the first subtype, gamblers who are driven by urge responded well to treatment with medications that block the brain opioid system (e.g., naltrexone) or certain receptors for the neurotransmitter glutamate (e.g., memantine). Grant also found that family history plays an important role in refining this group even further. People with a family history of addiction responded even better to the opioid blocker, which has been shown in other studies to decrease the urge to use substances such as alcohol.

The second subtype, gamblers who have difficulty inhibiting their behaviors and react to the smallest desires, respond well to medications that act on a specific enzyme, catechol-O-methyl-transferase (COMT), which plays a major role in the function of the prefrontal cortex. Researchers found that decreasing the function of COMT can increase one's ability to inhibit their desire to gamble.

"By understanding these different subtypes, we are able to target the core biology of the illness with individualized treatment," said Jon Grant, MD, JD, MPH, Associate Professor of Psychiatry at the University of Minnesota and ACNP member.

Disclaimer

NorthShore ADHD and Addiction Clinic maintains this web site as a health information resource for educational and informational purposes. It is not provided as a professional service or as a substitute for professional medical advice. If you have, or suspect you may have, a health condition, you should consult your health care provider, call 911 or visit your local Emergency services.

This Web site provides links to other health care resources that we make available simply as a convenience to our users. We do not endorse the content or recommend any products or services sold on such other sites. 

 

NorthShore ADHD and Addiction Clinic disclaims any responsibility or liability for any claim, loss or damage arising from the use of the information.

We are now virtual... you can reach us by

fax       778-945-2778

email   info@northshoreadhd.com